Burosumab in Unidentifiable Tumor-Induced Osteomalacia

Area of Science:

• Endocrinology
• Oncology
• Nephrology

Background:

• Tumor-induced osteomalacia (TIO) presents diagnostic and treatment challenges, often due to unresectable or occult primary tumors.
• Fibroblast growth factor 23 (FGF23) is implicated in the pathophysiology of TIO.
• Current treatment limitations exist, particularly regarding accessibility and subsidy status in certain regions like Australia.

Purpose of the Study:

• To evaluate the efficacy and role of burosumab as a first-line treatment for Tumor-induced osteomalacia (TIO).
• To highlight the potential of targeting FGF23 in managing TIO.
• To advocate for burosumab's consideration in clinical practice for TIO.

Main Methods:

• Clinical case review and treatment experience.
• Administration of burosumab, a monoclonal antibody targeting FGF23.
• Monitoring of biochemical and clinical parameters relevant to osteomalacia.

Main Results:

• Burosumab demonstrated effectiveness in treating Tumor-induced osteomalacia.
• The anti-FGF23 therapy addressed the underlying mechanism of TIO.
• Positive clinical outcomes were observed with burosumab treatment.

Conclusions:

• Burosumab is a viable and effective first-line therapy for Tumor-induced osteomalacia.
• Targeting FGF23 with burosumab offers a promising therapeutic strategy for TIO.
• Clinical guidelines and accessibility in Australia should be reviewed to facilitate burosumab use for TIO.